Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Standalone and Consolidated Unaudited Financial Results for the second quarter and half year ended 30.09.2026

THRU ONLINE FILING October 22, 2026 BSE Ltd. National Stock Exchange India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block-G, Dalal Street Bandra Kurla Complex, Bandra – (East) Mumbai 400 023 Mumbai-400051 Scrip Code : 524494 Scrip Code : IPCALAB Dear Sirs, Pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 5th November, 2026, inter-alia, to consider and take on record the Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended 30th September, 2026. Further, with reference to the above meeting of the Board of Directors, we have already informed vide our letter dated 22nd September, 2026 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with effect from 1st October, 2026 and until 48 hours after the declaration of the Company’s unaudited financial results, i.e., till 7th November, 2026. Thanking you. Yours faithfully For Ipca Laboratories Limited Harish P. Kamath Corporate Counsel & Company Secretary (ACS 6792)